Twelve Bio: Building a plug-and-play CRISPR platform with Cas12a variants

Twelve Bio is developing Cas12a variants for CRISPR-based diagnostics, therapeutics

Danish newco Twelve Bio is building a CRISPR-Cas12a toolbox comprising a suite of Cas12a variants that are more efficient, precise and safe to use than the wild type Cas12a enzyme for both diagnostic and therapeutic applications.

Twelve Bio spun out of the University of Copenhagen in 2019 with grant funding from Novo Seeds and Novo Nordisk Foundation’s BioInnovation Institute. Its co-founders are CEO Stefano Stella and Guillermo Montoya, both professors at the Novo Nordisk Foundation Center for Protein Research at the University of

Read the full 831 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers